Edesa Biotech, Inc. Income Statement
EDSA|7 years of annual SEC 10-K data (FY2014-FY2021)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 7 fiscal years. All figures from audited SEC 10-K filings.
Edesa Biotech, Inc. reported $328,801 in revenue and $6M in net loss for FY2021. Revenue has grown at a 2.0% compound annual rate over the past 7 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.47 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2021 | FY2020 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|
| Revenue | $328.8K | $410.9K | $228.3K | $758.7K | $372.1K | $545.5K | $286.1K |
| Cost of Revenue | $17.6K | $101.3K | $250.0K | $580.8K | $469.1K | $57.4K | $426.3K |
| SG&A Expense | $3.4M | $2.0M | $2.9M | $3.2M | $2.9M | $1.8M | $3.7M |
| R&D Expense | $3.3M | $1.1M | $2.0M | $1.0M | $2.5M | $2.0M | $2.6M |
| Operating Income | -$6.4M | -$2.8M | -$5.2M | -$4.3M | -$5.7M | - | - |
| Income Tax | $800 | $0 | $800 | $36.8K | $27.2K | $800 | $800 |
| Net Income | -$6.4M | -$2.8M | -$5.0M | -$2.8M | -$8.4M | -$14.5M | -$5.5M |
| EPS (Basic) | - | - | - | - | -$1.11 | -$2.81 | - |
| EPS (Diluted) | -$0.74 | -$0.55 | -$3.44 | -$0.36 | -$1.11 | -$2.81 | -$0.13 |
| Shares Outstanding | 9.6M | 7.5M | 1.5M | 10.1M | 8.0M | 7.8M | 57.9M |
| Operating Margin | -1946.7% | -689.3% | -2288.6% | -571.9% | -1536.7% | - | - |
| Profit Margin | -1935.3% | -675.8% | -2203.7% | -374.7% | -2267.9% | -2657.5% | -1933.0% |